Document is current

Article History

Received: 15 January 2024

Accepted: 25 April 2024

First Online: 17 May 2024

Declarations

:

: Kaname Nosaki has received research grants from Takeda, AstraZeneca, MSD K.K, Abbvie, Chugai Pharma, DaiichiSankyo/UCB Japan, and AnHeart Therapeutics and honoraria from AstraZeneca, Chugai Pharma, Lilly, MSD, Pfizer, Taiho Pharmaceutical, Janssen, Ono Pharmaceutical, Takeda, Novartis, and Merck and Advisory Board for Daiichi Sankyo/UCB Japan and Abbvie. Kiyotaka Yoh has received research grants from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi sankyo, Lilly, MSD, Pfizer, Taiho, Takeda and consultation for Boehringer Ingelheim and honoraria from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi sankyo, Janssen, Kyowa kirin, Lilly, Merck Serono, Novartis, Ono, Otsuka, Taiho, Takeda. Ryo Toyozawa has received research grants from Abbvie, Amgen, AnHeart Therapeutics, Daiichi Sankyo, Eli Lilly Japan, Novartis Pharma, Pfizer Japan, Takeda Pharmaceutical and honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Nippon, Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, Takeda Pharmaceutical. Hidehito Horinouchi has received research grants from MSD, Abbvie, AstraZeneca, BMS, Ono, Daiichi-Sankyo, Janssen, Chugai, Roche and honoraria from AstraZeneca, MSD, Eli Lilly, Ono, BMS, Chugai, Roche, Amgen, Abbvie and Advisory Board for AstraZeneca, Chugai, Roche, ONO, BMS, Abbvie. Masahiro Morise has received research grants from Boehringer-ingelheim, Eli Lilly and honoraria from Boehringer Ingelheim, Daiichi Sankyo, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, Merk Sharp & Dohme (MSD), Ono Pharmaceutical, and Taiho Pharmaceutical. and Principal investigator of pharmaceutical companies initiated trial for Chugai, Astra Zeneca, Ono, Pfizer, Merk serono, Kissei, Taiho and Novartis. Kadoaki Ohashi has received research grants from Nippon Boehringer Ingelheim Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., Eli Lilly Japan K.K., DAIICHI SANKYO COMPANY, LIMITED and honoraria from Eli Lilly Japan K.K., Novartis Pharma K.K., CHUGAI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd. Haruyasu Murakami has received research grants from Chugai pharma, AstraZeneca, AbbVie, Daiichi Sankyo, IQvia, Taiho Pharmaceutical, Bayer and honoraria from Chugai pharma, Daiichi Sankyo, AstraZeneca, Takeda, Amgen, Ono Pharmaceutical, Bristol-Myers Squibb Japan, MSD, Pfizer, Novartis, Lilly Japan, Taiho Pharmaceutical, Eisai, Nihonkayaku and Advisory Board for Chugai pharma, GAIA BioMedicine, Daiichi Sankyo, Amgen. Miyako Satouchi has received research grants from AstraZeneca, Ono, Bristol Myers Squibb, MSD, Janssen, Amgen, Taiho, Pfizer, Daiichi-Sankyo, Takeda, Eisai, Novartis, GlaxoSmithKline and honoraria from AstraZeneca, Chugai, Eli Lilly, Ono, Bristol Myers Squibb, MSD, Taiho, Pfizer, Novartis, Takeda, Merck, Novartis, Daiichi-Sankyo, Bayer, Amgen, Eisai. Jun Sakakibara-Konishi has received research grants from Lilly. Seiji Yano has received research grants from Takeda, Jansen and honoraria from Pfizer, Chugan, AstraZeneca, Eli Lilly, MSD, Ono, BMS, Amgen, Novartis. Shingo Matsumoto has received research grants from Chugai Pharma, Janssen Pharmaceutical, MSD and honoraria from Eli Lilly, Merck Biopharma, Chugai Pharma, Novartis Pharma, Guardant Health, AstraZeneca. Takashi Seto has received honoraria from Amgen, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, MSD, Novartis Pharma, Ono Pharmaceutical, Pfizer Japan, Takeda Pharmaceutical, Towa Pharmaceutical and employee of Precision Medicine Asia. Koichi Goto has received research grants from Amgen Inc., Amgen K.K., Amgen Astellas, BioPharma K.K., AstraZeneca K.K., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Craif Inc., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd. Ignyta,Inc., Janssen Pharmaceutical K.K., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Loxo Oncology, Inc., LSI Medience Corporation., MEDICAL& BIOLOGICAL LABORATORIES CO., LTD., Merck Biopharma Co., Ltd., Merus N.V., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Pfizer R&D Japan G.K., Precision Medicine Asia Co., Ltd., RIKEN GENESIS CO., LTD., Sumitomo Pharma Co., Ltd., Spectrum Pharmaceuticals, Inc., Sysmex Corporation., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Turning Point Therapeutics,Inc., Xcoo, Inc. and honoraria from Amgen K.K., Amoy Diagnosties Co.,Ltd., AstraZeneca K.K., Bayer U.S., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Guardant Health Inc., Janssen Pharmaceutical K.K., Merck Biopharma Co., Ltd., Nippon Kayaku Co.,Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., RIKEN GENESIS CO., LTD., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Thermo Fisher Scientific K.K. and Advisory Board for Amgen Inc., Amgen K.K., DAIICHI SANKYO Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Janssen Pharmaceutical K.K., SYNEOS HEALTH CLINICAL K.K.. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.